Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.43 |
| ▸ | DRD3 | P35462 | 8/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | CCKBR | P32239 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | GHSR | Q92847 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5643675 | 0.91 | F10 (0.39) | DRD2DRD3F10KCNH2GHSR | |
| SCHEMBL5641383 | 0.90 | F10 (0.44) | F10 | |
| SCHEMBL5640892 | 0.90 | HRH4 (0.45) | DRD3F10HRH4 | |
| SCHEMBL5639620 | 0.85 | F10 (0.43) | F10 | |
| SCHEMBL5643102 | 0.84 | F10 (0.46) | F10KDM4E | |
| SCHEMBL5642215 | 0.83 | F10 (0.42) | DRD2DRD3HTR2CF10OPRM1 | |
| SCHEMBL4593714 | 0.83 | SCN4A (0.47) | DRD2DRD3SCN4ASCN9ASCN3A | |
| SCHEMBL4594487 | 0.81 | F10 (0.45) | F10KCNH2 | |
| SCHEMBL5643197 | 0.81 | F10 (0.42) | F10 | |
| SCHEMBL5637657 | 0.81 | F10 (0.42) | F10HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199149-B2 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMANY | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | F2, F12, SPINT2 | DRD2 4648/4885DRD3 4454/4885SCN4A 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.